MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • All Meetings
    • 2026 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

Articles tagged "Pharmacotherapy"

  • 2022 International Congress

    Levodopa-carbidopa intestinal gel infusion and long-term tolerability in Parkinson’s: multicentre, international 13-year follow-up data

    V. Leta, L. Batzu, L. Williams, S. Waller, F. Garri, K. Rukavina, M. Parry, S. Jones, J. Griffith, N. Jeyakumar, M. Scharfenort, P. Odin, V. Metta, G. Chung-Faye, P. Dubois, T. Marshall, A. Zecchinelli, F. Del Sorbo, V. Viljaharju, E. Pekkonen, A. Antonini, V. Fung, K. Ray Chaudhuri (London, United Kingdom)

    Objective: To evaluate the long-term range and nature of Levodopa-carbidopa intestinal gel (LCIG) infusion-related complications in people with Parkinson’s (PwP). Background: LCIG infusion is an…
  • 2022 International Congress

    Continuous circadian intracerebroventricular administration of anaerobically preserved dopamine greatly reduces severe L-dopa-related complications in Parkinson’s disease

    C. Moreau, P. Odou, A. Demailly, G. Touzet, N. Reyns, N. Carta, C. Barthelemy, D. Lannoy, B. Palas, B. Gouges, JC. Devedjian, L. Defebvre, M. Fisichella, D. Devos (Lille, France)

    Objective: We aim to demonstrate the safety and efficacy of continuous circadian intracerebroventricular (i.c.v.) administration of anaerobic-dopamine (A-dopamine) to reduce the L-dopa-related complications (LDRC) in…
  • 2022 International Congress

    Efficacy of levodopa/benserazide dispersible tablet on delayed ON in Parkinson’s disease patients with motor fluctuations: a multicenter randomized open-label cross-over trial

    HJ. Chang, J. Park, S. Oh, CW. Shin, JW. Cho, JY. Lee (Seoul, Republic of Korea)

    Objective: This study aimed to assess the efficacy of levodopa/benserazide dispersible tablet on delayed ON in Parkinson’s disease (PD) patients with motor fluctuation. Background: Delayed…
  • 2022 International Congress

    Multiple N-of-1 trials to investigate hypoxia therapy in Parkinson’s disease: TALISMAN study rationale and protocol

    J. Janssen Daalen, M. Meinders, B. Stunnenberg, H. Groenewoud, P. Ainslie, D. Thijssen, B. Bloem (Nijmegen, Netherlands)

    Objective: This is the first study that will assess the potential impact of hypoxia-based therapy in individuals with PD on respiratory parameters and PD symptoms.…
  • 2022 International Congress

    Adverse drug reactions to apomorphine: a worldwide pharmacovigilancedatabase analysis

    M. Auffret, C. Le Corre, LM. Scailteux, M. Vérin, E. Polard (Rennes, France)

    Objective: To determine the safety profile of apomorphine (expected vs. new signals), regardless of the indication and route of administration. Background: Adverse drug reactions (ADR)…
  • 2022 International Congress

    Variability of Plasma Levodopa Conveniently Reduced by More Frequent Administration of Smaller Doses of Carbidopa/Levodopa Using a Novel Functionally Scored Formulation

    A. Al-Sabbagh, S. Testino, M. Koga, T. Chase, K. Smith (Alpharetta, USA)

    Objective: To evaluate the pharmacokinetics (PK) of 25/100 mg carbidopa (CD)/levodopa (LD) compared to half that amount given twice as often using a new, deeply…
  • 2022 International Congress

    Phantom Pregnancy – A Novel Impulse Control Behaviour in Parkinson’s Disease: A Case Report

    H. Martin, L. Teare (Coventry, United Kingdom)

    Objective: A case report of a phantom pregnancy in a patient with Parkinson’s disease (PD) resulting from impulse control behaviour. Background: Impulse Control Disorders (ICDs)…
  • MDS Virtual Congress 2021

    Long-Term Safety and Efficacy of Apomorphine Sublingual Film for “OFF” Episodes in Parkinson’s Disease: Europe vs North America

    R. Pahwa, S. Fox, J. Hui, C. Singer, J. Schwarz, M F. de Pandis, J. Raw, I. Zhang, E. Pappert, B. Navia (Kansas City, USA)

    Objective: Evaluate long-term safety (LTS), tolerability, and efficacy of apomorphine sublingual film (APL) for on-demand treatment of “OFF” episodes in patients with Parkinson’s disease (PD)…
  • MDS Virtual Congress 2021

    A Phase 2 Randomized Controlled Trial Repurposing Ambroxol as a Disease Modifying Treatment for Parkinson’s Disease Dementia.

    SH. Pasternak, C. Silviera, K. Coleman, E. Finger, J. Wells, M. Borrie, S. Morrow, G. Zou, R. Bartha, P. Macdonald, ME. Jenkins, M. Jog, R. Tirona, CA. Rupar (London, Canada)

    Objective: Currently there are no disease-treatments for Synucleinopathies including Parkinson’s disease dementia (PDD). Our objective is to use Ambroxol to target GBA/Glucocerebrosidase to treat PDD.…
  • MDS Virtual Congress 2021

    Indirect Comparison of Apomorphine Sublingual Film Versus Levodopa Inhalation Powder for “OFF” Episodes in Parkinson’s Disease

    A. Thach, M. Zichlin, N. Kirson, K. Yang, K. Gaburo, E. Pappert, D. Mehta, G. Williams (Marlborough, USA)

    Objective: Conduct a matching-adjusted indirect comparison (MAIC) of the efficacy of apomorphine sublingual film (APL) vs levodopa inhalation powder (CVT-301) for “OFF” episodes in Parkinson’s…
  • « Previous Page
  • 1
  • …
  • 12
  • 13
  • 14
  • 15
  • 16
  • …
  • 36
  • Next Page »

Related Sites

International Parkinson and Movement Disorder Society

The Society that manages the annual International Congress »

International Congress

The official website for the International Congress of Parkinson’s and Movement Disorders® »

  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2026 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley